Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide

TM Robinson, PV O'Donnell, EJ Fuchs, L Luznik - Seminars in hematology, 2016 - Elsevier
Allogeneic blood or bone marrow transplantation (BMT) is a potentially curative therapy for
high-risk hematologic malignancies not curable by standard chemotherapy, but the
procedure is limited by the availability of human leukocyte antigen-matched donors for many
patients, as well as toxicities including graft-versus-host disease (GVHD). Our group has
developed the use of high-dose post-transplantation cyclophosphamide (PTCy) to
selectively remove alloreactive T cells without compromising engraftment. This protocol has …